Showing results (101-110 of 119) with videos related to

Sort By:
Pageof 12
JACC. Advances|November 30, 2025
Valvular Heart Disease Interventional Trials From 2000 to 2024: A Systematic ReviewFrederick Berro Rivera, Chieh-Mei Tsai, Polyn Luz S Pine, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 ReceptorsBernard Barlaam, Judith Anderton, Peter Ballard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2010
AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancerD Mark Hickinson, Teresa Klinowska, Georgina Speake, et al.
Current Medical Research and Opinion|June 5, 2024
Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regressionFrederick Berro Rivera, Sung Whoy Cha, John Vincent Magalong, et al.
JACC. Advances|November 25, 2024
Enrollment of Females in Randomized Trials for Glucagon-Like Peptide 1 Receptor Agonists: A Systematic ReviewFrederick Berro Rivera, Mc John Caro Ybañez, John Vincent Magalong, et al.
American Journal of Preventive Cardiology|July 3, 2026
Impact of incretin therapies on biochemical and imaging outcomes in metabolic dysfunction-associated steatotic liver diseaseNicole Ann Tesoro, Frederick Berro Rivera, Nathan Ross B Bantayan, et al.
European Journal of Heart Failure|November 22, 2016
Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemiaPatrick Rossignol, Nicolas Girerd, George Bakris, et al.
Journal of Clinical Lipidology|June 21, 2024
Sex, racial, ethnic, and geographical disparities in major adverse cardiovascular outcome of glucagon-like peptide-1 receptor agonists among patients with and without diabetes mellitus: A meta-analysis of placebo-controlled randomized controlled trialsFrederick Berro Rivera, Nathan Ross B Bantayan, John Paul Aparece, et al.
Blood|August 14, 2012
Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphismsHervé Ghesquières, Guillaume Cartron, John Francis Seymour, et al.
Cardiorenal Medicine|February 21, 2023
Transcatheter Aortic Valve Replacement-Associated Acute Kidney Injury: An UpdateFrederick Berro Rivera, Abdullah Al-Abcha, Marie Francesca Mapua Ansay, et al.
Pageof 12